EMA Authorised: Rubraca (rucaparib camsylate) — pharmaand GmbH

View source ↗

Summary

The EMA authorises Rubraca (rucaparib camsylate) for ovarian neoplasms, with pharmaand GmbH as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• RUBRACA (RUCAPARIB)

Snippet

Status: Authorised. Therapeutic area: Ovarian Neoplasms. MAH: pharmaand GmbH. Decision date: 11/06/2026